National Resilience News and Resources

National Resilience, a leader in biomanufacturing, has expanded its collaboration with Parvus Therapeutics to support the development and manufacturing of PVT401, a drug candidate targeting Inflammatory Bowel Disease (IBD). The partnership builds on the successful work done on Parvus’ previous

National Resilience, a technology-focused biomanufacturing company, has announced a significant investment of $225 million into its Ohio facility. By 2025, it aims to produce more than 200 million units across its network for various types of treatments, including the widely